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ABSTRACT
Wild-type p53 tumor suppressor activity in neuroblastoma tumors is hampered by 
increased MDM2 activity, making selective MDM2 antagonists an attractive therapeutic 
strategy for this childhood malignancy. Since monotherapy in cancer is generally not 
providing long-lasting clinical responses, we here aimed to identify small molecule 
drugs that synergize with idasanutlin (RG7388). To this purpose we evaluated 15 
targeted drugs in combination with idasanutlin in three p53 wild type neuroblastoma 
cell lines and identified the BCL2 inhibitor venetoclax (ABT-199) as a promising 
interaction partner. The venetoclax/idasanutlin combination was consistently found 
to be highly synergistic in a diverse panel of neuroblastoma cell lines, including 
cells with high MCL1 expression levels. A more pronounced induction of apoptosis 
was found to underlie the synergistic interaction, as evidenced by caspase-3/7 and 
cleaved PARP measurements. Mice carrying orthotopic xenografts of neuroblastoma 
cells treated with both idasanutlin and venetoclax had drastically lower tumor weights 
than mice treated with either treatment alone. In conclusion, these data strongly 
support the further evaluation of dual BCL2/MDM2 targeting as a therapeutic strategy 
in neuroblastoma.
INTRODUCTION
Neuroblastoma, the second most common solid 
tumor in childhood, is characterized by a heterogeneous 
clinical behavior, ranging from spontaneous regression 
to aggressive and inexorable disease [1]. Fifty percent of 
cases are considered high risk, with long-term survival 
rates after multimodal chemo- and immunotherapy below 
40% [2]. Like many childhood cancers, mutations in 
the TP53 tumor suppressor gene are rarely encountered 
in primary neuroblastoma tumors (< 2%), and remain 
rather uncommon at relapse (< 15%) [3, 4]. However, 
neuroblastoma cells with wild-type TP53 almost 
invariably harbor defects in other components of the 
TP53 pathway. In particular, amplification and increased 
expression of MDM2 and suppression of CDKN2A 
(p14ARF) have been reported. These abnormalities converge 
into the central CDKN2A/MDM2/TP53 axis resulting in 
increased activity of MDM2, the principal TP53 inhibitor, 
and subsequent impairment of normal TP53 functioning 
[5]. The importance of MDM2-mediated suppression of 
the TP53 pathway in neuroblastoma has convincingly been 
demonstrated in vivo using an MDM2-haploinsufficient 
mouse model in which tumor latency was delayed while 
tumor incidence and growth were remarkably reduced [6].
These biological conditions appear to make 
neuroblastoma cells highly sensitive to treatment with 
MDM2 antagonists. Indeed, the anti-tumor effects of 
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nutlin-3, a cis-imidazoline analogue that selectively 
disrupts the interaction between TP53 and MDM2 
resulting in targeted activation of the TP53 pathway, 
have extensively been reported in neuroblastoma [7–11]. 
Treatment with nutlin-3 resulted in nuclear accumulation 
of TP53, transcriptional activation of TP53 target 
genes and subsequent induction of cell cycle arrest and 
apoptosis both in vitro and in vivo. While initial studies 
in neuroblastoma have been performed using the original 
lead compound, nutlin-3, second-generation inhibitors 
with superior potency and selectivity, such as RG7388 
(idasanutlin), are now prioritized for clinical development 
[12, 13]. Investigation of the clinical trial drug idasanutlin 
in preclinical model systems of neuroblastoma is still 
limited. Successful introduction of targeted therapeutics in 
the clinic requires the identification of well-matched drugs 
for combination therapy to increase therapeutic efficacy 
and to prevent the development of treatment resistance. 
Resistance of neuroblastoma cells to nutlin-3 was found 
to be mainly mediated by the acquisition of de novo 
mutations in the TP53 DNA binding domain and to result 
in a multi-drug resistant phenotype [14]. In several cancer 
entities, experimental drug combinations with nutlin-3 
have been investigated [15, 16]. In neuroblastoma, reports 
have mainly been limited to chemotherapeutics that 
enhance the efficacy of MDM2 antagonists [8, 17–19]. To 
identify targeted drugs that could potentiate the anti-tumor 
effects of idasanutlin, we evaluated 15 targeted drugs in 
combination with idasanutlin in neuroblastoma cells. The 
highest degree of synergism was consistently observed 
if idasanutlin was combined with the BCL2/BCL-XL 
inhibitor ABT-263. A comparable strong synergistic 
activity was recorded if idasanutlin was combined with 
the more selective BCL2 inhibitor ABT-199 (venetoclax), 
irrespective of basal BCL2 and MCL1 expression levels. 
In neuroblastoma cells, the combination therapy resulted 
in increased induction of apoptosis compared to either 
treatment alone, consistent with the proposed mechanism 
of action. In addition, when administered to mice carrying 
orthotopic xenografts of human neuroblastoma cells, 
the combination of idasanutlin and venetoclax was 
significantly more effective than either treatment alone.
RESULTS
Combining ABT-263 and idasanutlin is highly 
synergistic in neuroblastoma cells
We selected three neuroblastoma cell lines with 
wild-type TP53 (SH-SY5Y, IMR-32 and NGP) and 
used one TP53 mutant cell line (SK-N-BE(2c)) as a 
negative control. We evaluated combination treatment 
of idasanutlin with 15 other targeted drugs, selected 
on their ability to target pathways that are considered 
important in neuroblastoma biology (Supplementary 
Table 1 provides a detailed overview of used compounds 
and concentration ranges). We exposed neuroblastoma 
cells to a concentration series of either idasanutlin or 
one of the other compounds or a combination of both 
for 24 hours after which cell viability and CI values 
were determined (Figure 1). In all three cell lines with 
wild-type TP53, we found that the combination of the 
BCL2/BCL-XL antagonist ABT-263 (navitoclax) with 
idasanutlin consistently resulted in highly synergistic CI 
values: 0.29, 0.27 and 0.25 for NGP, IMR-32 and SH-
SY5Y, respectively. In contrast, we did not observe any 
effects in SK-N-BE(2c) cells using the same dose range 
(Supplementary Table 2). These results point to a highly 
synergistic interaction between idasanutlin and ABT-263 
in neuroblastoma cells. Furthermore, we found YM155, 
a small molecule that inhibits the transactivation of the 
anti-apoptotic protein survivin (BIRC5), to potently 
enhance the efficacy of idasanutlin in the TP53 wild-type 
neuroblastoma cells, with CI values of 0.62, 0.38 and 
0.41 for NGP, IMR-32 and SH-SY5Y, respectively. The 
anti-apoptotic BCL-XL, BCL2 and survivin proteins have 
been described to counteract TP53-mediated apoptosis 
and inhibition of these proteins has been shown to lower 
the threshold for apoptosis and to enhance the efficacy of 
TP53 reactivation therapies [20, 21].
Venetoclax and idasanutlin are highly synergistic 
in human neuroblastoma cell lines
BCL2 is an anti-apoptotic member of the 
BCL2 protein family and is often highly expressed in 
neuroblastoma tumors. BCL2 and MCL1 expression levels 
are correlated with the efficacy of BCL2 antagonists in 
neuroblastoma cells [22, 23]. Therefore, we determined 
BCL2 and MCL1 RNA and protein expression levels 
by RT-qPCR and Western Blotting, respectively, in a 
panel of neuroblastoma cell lines (Figure 2A, 2B). As 
described previously, we observed that neuroblastoma 
cells express either BCL2, MCL1 or both [22]. Moreover, 
we found discordance between BCL2/MCL1 protein and 
RNA expression levels, pointing to posttranscriptional 
regulation mechanisms. In order to assess whether 
combined treatment of ABT-263 and idasanutlin could 
have a broad therapeutic applicability in neuroblastoma, 
we evaluated both compounds in 10 human neuroblastoma 
cell lines with varying MCL1 and BCL2 expression levels. 
We treated cells for 24 hours with idasanutlin, ABT-263 
or both and determined cell viability and CI values. 
With exception of the SH-EP cell line, that has a known 
inherent resistance to p53 activation, we found that the 
ABT-263/idasanutlin combination is highly synergistic 
in all evaluated neuroblastoma cell lines, with CI values 
ranging from 0.03 to 0.66 (Figure 2C). The occurrence 
of synergism was found independent of MCL1 and 
BCL2 expression levels, but higher drug concentrations 
had to be used in cells with low BCL2 expression levels 
to achieve therapeutic effect, which is in line with 
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previous reports demonstrating that the efficacy of BCL2 
antagonists is dependent on BCL2 expression levels 
[22, 23]. A mechanism-based thrombocytopenia due to 
BCL-XL binding has prevented the clinical development 
of ABT-263 and has stimulated the development of 
venetoclax, an analogue with negligible binding capacity 
for BCL-XL [24–26]. We therefore decided to evaluate 
the combinatorial treatment in our cell line panel with 
idasanutlin and venetoclax (Figure 2C). For all studied 
cell lines, we observed similar CI values when combining 
either venetoclax or ABT-263 with idasanutlin, with 
CI values between 0.004 and 0.69 indicative of strong 
synergism.
Combined venetoclax/idasanutlin treatment 
enhances induction of apoptosis
As the majority of neuroblastoma tumors is 
dependent on high BCL2 expression levels for survival, we 
evaluated the effects of combined venetoclax/idasanutlin 
treatment on cell viability and apoptosis in neuroblastoma 
cell lines with high BCL2 expression levels. Cell viability 
was determined 24 hours after SMS-KCNR, LAN-5, SH-
SY5Y and CLB-GA cells were treated with idasanutlin, 
venetoclax or a combination of both (Figure 3). In all four 
cell lines the combination therapy dramatically reduced 
cell viability compared to each treatment alone. According 
to the proposed mechanism of action, combined treatment 
of idasanutlin and venetoclax should potently induce 
apoptosis [27]. In keeping with this hypothesis, we 
observed a significantly higher increase in caspase-3 and 
caspase-7 activity when combining both compounds as 
compared to single compound exposure in all cell lines 
(Figure 4A). Similar results were observed when PARP 
cleavage was assessed using Western blotting (Figure 4B). 
Next, we evaluated the protein levels of PUMA and BAX, 
two downstream mediators of p53-induced apoptosis and 
of the anti-apoptotic proteins MCL1 and BCL2, 24 hours 
after SMS-KCNR, LAN-5, SH-SY5Y and CLB-GA 
cells had been treated with idasanutlin, venetoclax or a 
combination of both (Figure 5). We observed increased 
protein abundance of pro-apoptotic PUMA and BAX upon 
idasanutlin treatment in all four neuroblastoma cell lines. 
BCL2 protein abundance was unaffected by treatment with 
either of the two drugs, with the exception of SMS-KCNR 
cells in which we observed higher BCL2 levels after 
treatment with the combination of both drugs. In addition, 
and in contrast to previous reports in acute myeloid 
leukemia cells [28], we did not observe a downregulation 
of MCL1 protein levels upon treatment with idasanutlin.
Dual targeting of BCL2 and MDM2 inhibits 
neuroblastoma tumor growth in vivo
Despite a high degree of homology between murine 
and human MDM2, MDM2 antagonists have reduced 
binding affinity for mouse MDM2 in comparison to its 
human counterpart [15]. This interspecies selectivity 
Figure 1: Heatmap with CI values of 15 targeted drugs combined with idasanutlin in NGP, IMR-32 and SH-SY5Y 
cells. Cell viability and CI values were determined 24h after treatment with idasanutlin and one of the selected compounds. Depicted CI 
values represent the average of the CIs at ED50, ED75 and ED90 of at least two independent experiments. > 10: very strong antagonism; 
3.30–10: strong antagonism; 1.45–3.30: antagonism; 1.20–1.45: moderate antagonism; 1.10–1.20: slight antagonism; 0.90–1.10: nearly 
additive; 0.85–0.90: slight synergism; 0.70–0.85: moderate synergism; 0.30–0.70: synergism; 0.10–0.30: strong synergism; < 0.10: very 
strong synergism. Not for all compounds these effective doses could be achieved within a therapeutic range. For SK-N-BE(2c) no CI values 
could be calculated.
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hampers the use of murine transgenic models for the 
in vivo evaluation of MDM2 antagonists and prompted us 
to use a well-established model system utilizing orthotopic 
neuroblastoma xenografts. This model closely resembles 
the growth characteristics of primary neuroblastoma 
arising from the para-adrenal location in humans [29]. For 
the evaluation of the idasanutlin/venetoclax combination, 
nude mice carrying orthotopic xenografts of human 
Figure 2: (A) BCL2 and MCL1 expression measured with RT-qPCR in a panel of neuroblastoma cell lines. Columns represent the 
normalized relative expression values and error bars represent the corresponding standard error. (B) Immunoblot analysis of BCL2 and 
MCL1 in neuroblastoma cell lines with β-actin as loading control. (C) Heatmap with CI values determined 24 hours after treatment 
with idasanutlin combined with venetoclax or ABT-263 in neuroblastoma cells. Depicted CI values represent the average of the CIs at 
ED50, ED75 and ED90 of at least two independent experiments. > 10: very strong antagonism; 3.30–10: strong antagonism; 1.45–3.30: 
antagonism; 1.20–1.45: moderate antagonism; 1.10–1.20: slight antagonism; 0.90–1.10: nearly additive; 0.85-0.90: slight synergism; 0.70–
0.85: moderate synergism; 0.30-0.70: synergism; 0.10–0.30: strong synergism; < 0.10: very strong synergism.
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SH-SY5Y/Luc cells were treated by oral gavage 
with vehicle control, 75 mg/kg idasanutlin, 75 mg/kg 
venetoclax or both drugs once daily, six times a week. 
After three weeks of treatment, mice were sacrificed and 
tumors were collected and weighed. When comparing with 
the control condition, we observed a significant reduction 
in tumor weight for mice treated with idasanutlin 
(p < 0.05, Mann–Whitney test) but not for mice treated 
with venetoclax (Figure 6). In mice treated with vehicle 
control, the average tumor weight was found to be 1.98 
g (n = 8), compared to 0.95 g (n = 7) in mice treated 
with idasanutlin and 1.43 g (n = 10) in mice treated 
with venetoclax (Figure 5). This observation is in line 
with our in vitro findings (Figure 3). Most importantly, 
tumor weights of mice treated with both idasanutlin and 
venetoclax were found to be drastically lower than tumor 
weights of mice treated with either compound alone 
(p < 0.01 and p < 0.001 when comparing with idasanutlin 
and venetoclax respectively, Mann–Whitney test), with an 
average tumor weight of 0.35 g (n = 10). Mouse weights, 
possibly indicative of toxicity, were significantly lower in 
mice treated with idasanutlin (p < 0.05, Mann–Whitney 
test), but no significant difference was observed between 
the monotherapy and combination groups suggesting 
no additive adverse effects of the drug combination 
(Supplementary Figure 1). 
To confirm these findings in an independent model 
system, we established orthotopic xenograft tumors of 
SMS-KCNR/luc human neuroblastoma cells in nude 
mice and administered 75 mg/kg idasanutlin or 50 mg/kg 
Figure 3: Effect of idasanutlin, venetoclax or both on neuroblastoma cell viability. Exponentially growing neuroblastoma 
cells with high BCL2 expression (LAN-5, SMS-KCNR, CLB-GA and SH-SY5Y) were exposed to a range of idasanutlin and venetoclax 
concentrations for 24 hours and the percentage cell viability with respect to vehicle-treated controls was determined. Points represent the 
average of two independent experiments, each done in duplicate. Error bars represent the standard deviation. 
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venetoclax or the combination of both treatments or 
vehicle control once daily by oral gavage for two 
weeks. Tumor weights at the end of the treatment 
period were on average 0.8 g (n = 9) in mice treated 
with the combination treatment regimen and 
2.08 g (n = 6) in vehicle-treated mice, which reflected a 
significantly stronger tumor growth inhibition than after 
treatment with either drug alone (p < 0.05 and p < 0.01 
when comparing with idasanutlin and venetoclax, 
respectively; Mann–Whitney test; Supplementary 
Figure 2). In conclusion, these in vivo data confirm our 
in vitro findings and strongly support further exploration 
of combined inhibition of MDM2 and BCL2 in the 
context of neuroblastoma.
DISCUSSION
Small molecule MDM2 antagonists represent a 
potential novel therapeutic strategy for neuroblastoma 
treatment. Nutlin-3 is a cis-imidazoline analogue that 
specifically targets the hydrophobic p53-binding pocket 
of MDM2 and has shown prominent efficacy against 
p53wt neuroblastoma cells both in vitro as in vivo [16]. 
RG7112, a nutlin drug with improved pharmacological 
Figure 4: (A) Combined caspase-3 and caspase-7 activity in SH-SY5Y, SMS-KCNR, LAN-5 and CLB-GA cells after treatment with 
125 nM or 250 nM of idasanutlin and/or venetoclax for 24 hours relative to vehicle-treated control cells. Caspase-3/7 activity was higher 
when cells were treated with venetoclax and idasanutlin as compared to each compound alone. Columns represent the average of two 
different experiments, each done in duplicate. Caspase-3/7 activity of the idasanutlin-venetoclax combination was compared to idasanutlin 
and venetoclax alone using the Mann–Whitney test. *p < 0.05. Error bars represent the standard deviation. (B) Immunoblot analysis of 
PARP cleavage in SH-SY5Y, SMS-KCNR, LAN-5 and CLB-GA cells after treatment with either 62.5 nM (+), 125 nM (++), or 250 nM 
(+++) of idasanutlin and/or venetoclax for 24 hours. Cleavage of PARP, a hallmark of apoptosis, was evident after combined idasanutlin / 
venetoclax treatment in all four cell lines. Vinculin was used as a loading control.
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Figure 5: Immunoblot analysis of proteins involved in the p53 pathway and apoptosis. SH-SY5Y, SMS-KCNR, LAN-5 and 
CLB-GA cells were treated with either 62.5 nM (+), 125 nM (++), or 250 nM (+++) of idasanutlin and/or venetoclax for 24 hours. After 
24 hours of treatment, the protein abundance of p53, BAX, PUMA, MCL1 and BCL2 was determined by immunoblot analysis. Vinculin 
was used as loading control. 
Figure 6: Tumor weights after 3 weeks of treatment with idasanutlin, venetoclax or both. Nude mice carrying 
orthotopic xenografts of human SH-SY5Y/luc cells were treated by oral gavage with vehicle control, 75 mg/kg idasanutlin, 75 mg/kg 
venetoclax or both drugs, once daily, six times a week, for three weeks. Tumor weights were compared using the Mann–Whitney test. 
*p < 0.05, **p < 0.01, ***p < 0.001, n.s: not significant. 
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properties provided biomarker-based evidence of clinical 
activity in a proof-of-mechanism trial in adult patients 
with well-differentiated or dedifferentiated liposarcoma 
[30]. Two recent preclinical studies have shown marked 
anti-neuroblastoma activity of idasanutlin, a second-
generation MDM2 antagonist with superior potency and 
selectivity that is now prioritized for clinical development 
[19, 31]. Due to the development of resistance 
mechanisms, single-agent activity may however not prove 
sufficient to achieve sustained clinical efficacy of MDM2 
antagonists [14]. Therefore, combination treatment of 
MDM2 antagonists with other drugs eliciting strong 
synergistic effects could result in more durable therapy 
responses and lower relapse rates while avoiding toxicity. 
Preclinical investigation of the combination of idasanutlin 
with chemotherapeutic agents in neuroblastoma has 
recently put forward temozolomide and busulfan as 
well-suited chemotherapeutic combination partners for 
idasanutlin [19]. In this study we aimed to provide a 
rational framework for combining idasanutlin with small 
molecule drugs. 
We consistently found a high degree of synergism 
when combining idasanutlin with the BH3-mimetic ABT-
263 in p53wt cell lines and obtained similar results with 
venetoclax, a specific BCL2 inhibitor not targeting BCL-
XL to safeguard against on-target thrombocytopenia. 
BCL2 is an anti-apoptotic member of the BH3 family 
and is highly expressed in the majority of neuroblastoma 
tumors. The efficacy of BCL2 inhibition has been 
extensively demonstrated using both in vitro and in vivo 
model systems of neuroblastoma [22, 23, 32–34]. In these 
studies, high endogenous levels of MCL1 have been 
reported to contribute to resistance to the cancer killing 
potential of BH3 mimetics. In contrast to the efficacy of 
monotherapy, we found that the venetoclax/idasanutlin 
combination is synergistic independent of MCL1 or 
BCL2 expression levels, suggesting a wide applicability 
in neuroblastoma. In neuroblastoma, nutlin-induced 
apoptosis is at least partially mediated by transcriptional 
activation of pro-apoptotic BCL2 family members like 
BAX and PUMA [7]. Apoptosis can be viewed as a process 
that is initiated when an apoptotic threshold is crossed as a 
result of BCL2 or MCL1 inhibition. BH3 mimetics lower 
the apoptotic threshold owing to their interaction with 
these anti-apoptotic BCL2 family members and could in 
this way potentiate p53-induced apoptosis [27]. Here, we 
observed elevated levels of apoptosis when combining 
venetoclax and idasanutlin compared to each treatment 
alone, as evidenced by increased PARP cleavage and 
increased caspase-3/7 activity, suggesting similar kinetics 
are present in neuroblastoma. 
Interestingly, it has been reported that treatment of 
neuroblastoma cells with venetoclax can lead to increased 
levels of MCL1, resulting from a decreased expression 
of NOXA and increased stabilization by BIM [32]. 
Increased expression of MCL1 is a known resistance 
factor against treatment with BCL2 antagonists in various 
cancer types, including neuroblastoma [35]. Moreover, 
knockdown of MCL1 combined with venetoclax treatment 
results in synergistic growth inhibition of neuroblastoma 
cells [32, 36]. Since in acute myeloid leukemia the 
combination of idasanutlin with venetoclax results in an 
accelerated downregulation of MCL1 and subsequent 
induction of apoptosis [28], the same might hold true 
in neuroblastoma, providing an alternative explanation 
for the synergistic effects of this drug combination. We 
however observed increased protein levels of the apoptotic 
mediators PUMA and BAX upon idasanutlin treatment of 
neuroblastoma cells, but no downregulation of MCL1 
protein or any effects on BCL2 protein abundance. Since 
we evaluated protein levels in neuroblastoma cell lines 
with high BCL2 expression levels and not in MCL1-
dependent cell lines, it cannot be excluded that MCL1 
is downregulated by idasanutlin treatment in the latter. 
Given these considerations, it might be interesting to 
determine the exact molecular mechanism in distinct 
types of neuroblastoma cell lines and to evaluate whether 
combined treatment with idasanutlin and venetoclax could 
overcome high MCL1 expression in an MCL1-inducible 
or venetoclax-resistant model system of neuroblastoma.
In conclusion, this study demonstrates both in vitro 
and in vivo that idasanutlin and venetoclax have highly 
synergistic anti-tumor effects in neuroblastoma. It is our 
hope that the results presented in this study may contribute 
to the development of clinically relevant targeted treatment 
schemes for this childhood tumor.
MATERIALS AND METHODS
Cell culture and compound treatment 
Neuroblastoma cell lines used in this study (NGP, 
IMR-32, SH-SY5Y, SK-N-BE(2c), LAN-5, CLB-GA, 
SMS-KCNR, LAN-6, NB-1, STA-NB-12, SH-EP, STA-
NB-3, SMS-KAN, UKF-NB3, SJNB-10, NBL-S, TR-14, 
Kelly, STA-NB-8, SK-N-SH, SK-N-BE, ACN, STA-
NB-9, CHP-902R, CHP-134) were grown as monolayers 
in RPMI 1640 supplemented with 10% FCS, antibiotics 
and glutamine and maintained at 37°C and 5% CO2 in a 
humidified atmosphere. All cell lines used were genotyped 
to verify their identity. The following compounds were 
used: idasanutlin (kindly provided by Roche), venetoclax 
(Selleck Chemicals), ABT-263 (Selleck Chemicals), 
BI6727 (Selleck Chemicals), bortezomib (Selleck 
Chemicals), crizotinib (Sigma Aldrich), fenretinide 
(Tocris Bioscience), JQ1 (Gentaur), lestaurtinib (Sigma 
Aldrich), MLN8237 (Selleck Chemicals), PD332991 (Bio-
Connect), rapamycin (Sigma-Aldrich), SJ172550 (Tocris 
Bioscience), tenovin-6 (Cayman Chemicals), U0126 
(Sigma Aldrich), vorinostat (Sigma Aldrich), YM155 
(Selleck Chemicals). A stock solution was made in either 
ethanol or DMSO and kept at −20°C. Cells were exposed 
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to the indicated concentrations of compound for 24 hours 
with concentrations of DMSO and ethanol kept constant. 
Cell viability assays
Cells were plated at 80% confluency in duplicate 
wells in 96-well plates, incubated for at least 6 hours 
to permit adherence and treated with the indicated 
compounds for 24 hours. Cell viability was measured 
using the CELLtiter GLO Luminescent Cell Viability 
assay (Promega) according to the manufacturer’s 
instructions. At least two independent experiments were 
performed.
Antibodies and western blotting
Cells were lysed using RIPA buffer with protease 
and phosphatase inhibitor cocktail (Roche). Protein 
concentration was quantified using the BCA method and 
immunoblotting was performed according to standard 
procedures. Proteins were fractionated using 10% SDS 
polyacrylamide gels (Bio-Rad) and transferred to a 
nitrocellulose membrane (Bio-Rad). The following 
primary antibodies were used: TP53 (#OP43, 1:1000) 
from Millipore, PUMA (#4976S, 1:1000), MCL1 
(#5453S, 1:1000), cleaved PARP (#9546, 1:2000), BCL2 
(#2872, 1:1000), vinculin (#4650P, 1:10000) from Cell 
Signaling, BAX (#2774P, 1:2000) from Merck Chemicals. 
The following secondary antibodies were used: anti-
rabbit horseradish peroxidase (HRP, #7074S, 1:5000) and 
anti-mouse HRP (#7076S, 1:5000) from Cell Signaling. 
Proteins were visualized using Super Signal West Dura 
Extended Duration Substrate (Perbio Science). 
Apoptosis assays
For quantification of apoptosis, cells were plated 
in 96-well plates at 80% confluency, incubated for at 
least 6 h and exposed for 24 h to the indicated compound 
concentrations. Combined activity of caspase-3 and 
caspase-7 was determined using the Caspase-3/7 Glo assay 
(Promega) and measured with the Glomax multi detection 
system (Promega). At least two independent experiments 
were performed.
Calculation of combination index (CI) values
Cell viability was determined as described above 
using a constant-ratio design. At least two independent 
experiments were performed. Cell viability values were 
converted to relative compound effect values and the 
CI values were calculated using Calcusyn software 
v.2 (Biosoft) according to Chou & Talalay (1984) [37]. 
Depicted CI values represent the average of the CI values 
at effective dose 50, 75 and 90 (ED50, ED75 and ED90).
Orthotopic xenograft model
Orthotopic neuroblastoma xenografts were generated 
in four to six week old female athymic immunodeficient 
(Nu/Nu) mice as previously described [29]. Briefly, 1 × 106 
human SH-SY5Y/luc or SMS-KCNR/luc neuroblastoma 
cells were surgically implanted beneath the renal capsule 
encompassing the renal gland and kidney. Approximately 
two weeks after implantation, tumor establishment was 
confirmed by bioluminescent luciferase imaging and 
treatment was started. Mice carrying tumors of SH-
SY5Y/luc cells were treated with 75 mg/kg idasanutlin 
(dissolved in hydroxypropylcellulose/Tween-80), 75 mg/kg 
venetoclax (dissolved in 60% Phosal, 30 % PEG and 10 % 
ethanol) or both by oral gavage on a daily basis, six times 
a week, for a total of three weeks.  Mice carrying tumors 
of SMS-KCNR/luc cells were treated with 75 mg/kg 
idasanutlin (dissolved in hydroxypropylcellulose/
Tween-80), 50 mg/kg venetoclax (dissolved in 60% Phosal, 
30% PEG and 10% ethanol) or both by oral gavage on a 
daily basis, five times a week, for a total of two weeks. 
Idasanutlin and venetoclax were kindly provided by 
Roche and AbbVie, respectively. After treatment, mice 
were sacrificed and tumors were collected and weighed. 
All experimental protocols were approved by the Ethical 
Committee of Baylor College of Medicine and carried out 
in accordance with the relevant guidelines and regulations.
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